Combining SGLT-2 Inhibitors and GLP-1–Receptor Agonists for CV Risk Reduction in Type 2 Diabetes

There is much excitement about the emerging evidence on sodium–glucose cotransporter-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1)–receptor agonists. Each class can reduce cardiovascular (CV) risk. However, it is an open question whether together they would produce even greater benefit.

In the industry-funded AMPLITUDE-O trial (NCT03496298), efpeglenatide, a GLP-1–receptor agonist that is not yet FDA-approved, reduced the risk for CV and renal outcomes in people with type 2 diabetes and either CV or renal disease. They stratified the randomization by baseline or anticipated use of SGLT-2 inhibitors.

Among the 4076 trial participants, 33% were women, and the average age was 65 years. With a median follow-up of 1.8 years, efpeglenat…